Beam Therapeutics Inc. (BEAM) — 10-Q Filings
All 10-Q filings from Beam Therapeutics Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Beam Therapeutics' Q3 Loss Widens Amid Soaring R&D Costs
— Nov 4, 2025 Risk: high
Beam Therapeutics Inc. reported a net loss of $112.7 million for the three months ended September 30, 2025, an increase from a net loss of $96.7 million in the -
Beam Therapeutics' Q2 Loss Widens to $130.6M Amid R&D Surge
— Aug 5, 2025 Risk: high
Beam Therapeutics Inc. reported a net loss of $130.6 million for the three months ended June 30, 2025, a significant increase from the $105.3 million net loss i -
Beam Therapeutics Files Q1 2025 10-Q
— May 6, 2025 Risk: medium
Beam Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, located at 26 Landsdowne Street, Cambridge, MA, reported on its financi -
Beam Therapeutics Files Q3 2024 10-Q
— Nov 5, 2024 Risk: medium
Beam Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position, including details on its common -
Beam Therapeutics Q2 2024: Assets at $2.1B, Retained Earnings Negative
— Aug 6, 2024 Risk: high
Beam Therapeutics Inc. reported its Q2 2024 results, with total assets reaching $2.1 billion as of June 30, 2024. The company's retained earnings were negative -
Beam Therapeutics Files 10-Q for Period Ending March 31, 2024
— May 7, 2024 Risk: medium
Beam Therapeutics Inc. (BEAM) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Beam Therapeutics reported financial results for the quarter ended Ma
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX